Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

ABSTRACT:

SUBMITTER: Garassino MC 

PROVIDER: S-EPMC7771363 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature